STAT+: One of the most consequential years for cancer treatment, ever — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck and Moderna reported success of their personalized mRNA neoantigen cancer vaccine in a late-stage melanoma clinical trial, announced the day before the article
- Revolution Medicines reported success with a KRAS-targeted drug earlier this spring of 2026, cited alongside the Merck/Moderna result as a complementary breakthrough
- The two developments led STAT's biotech correspondent to characterize 2026 as potentially "one of the most consequential years in cancer treatment, ever," framing the pair as a once-in-a-generation convergence
Why it matters: Two late-stage oncology breakthroughs — a personalized mRNA neoantigen vaccine for melanoma and a KRAS-targeted therapy — landed in the same calendar year, hitting two of the field's hardest targets simultaneously. If both results hold, the combination repositions treatment options for cancer types where progress has stalled for decades.
Ask SkimNews
